Learn the data to support LA PrEP including both efficacy and safety data from the major clinical trials that led to the approval of cabotegravir for PrEP.
Jason Schafer, PharmD, MPH
Format: Microsoft PowerPoint (.ppt)
File Size: 1.09 MB
Released: February 16, 2022
Acknowledgements
Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare
Leaving the CCO site
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.
